ChemoCentryx, Inc. announced the appointment of William (Bill) Fairey as Executive Vice President and Chief Operating Officer. In this newly created position, Mr. Fairey will lead the Company's commercial strategy, including the development and execution of the company's commercialization plans for avacopan and CCX140, as well as oversee other key operational functions of the company. Bill brings extensive commercial strategy and operations expertise as well as a proven ability to develop and lead marketing efforts in North America and Asia Pacific. Mr. Fairey brings to ChemoCentryx over 25 years of substantial pharmaceutical industry commercial experience. His most recent position was President of Actelion Pharmaceuticals U.S. (2013-2017), where he led Actelion's sales, marketing, medical, access and regulatory activities.